Influence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 62, Issue 3, 2006, Pages 241-246

  Zerrouk, N ^a   Corti, G ^b   Ancillotti, S ^b   Maestrelli, F ^b   Cirri, M ^b   Mura, P ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Caco 2 cells; Chitosan; Cyclodextrins; Glyburide; Permeability; Solubility

Indexed keywords

CHITOSAN; CYCLODEXTRIN DERIVATIVE; GLIBENCLAMIDE; MACROCYCLIC COMPOUND;

ARTICLE; CANCER CELL CULTURE; COLON ADENOCARCINOMA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG SOLUBILITY; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION;

ALGORITHMS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLODEXTRINS; ELECTRIC CONDUCTIVITY; EXCIPIENTS; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; L-LACTATE DEHYDROGENASE; PERMEABILITY; SOLUBILITY;

EID: 33644827423     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2005.08.010     Document Type: Article

References (47)

1. L. Groop, E. Wahlin-Boll, K.J. Totterman, A. Melander, E.M. Tolppanen, and F. Fyhrqvist Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetes Eur. J. Clin. Pharmacol. 28 1985 697 704
2. J.B. Chalk, M. Patterson, M.T. Smith, and M.J. Eadie Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide Eur. J. Clin. Pharmacol. 31 1986 177 182
3. H. Blume, S.L. Ali, and M. Siewert Pharmaceutical quality of glibenclamide products: a multinational postmarket comparative study Drug Dev. Ind. Pharm. 19 1993 2713 2741
4. D. Cordes, and B.W. Müller Deactivation of amorphous glibenclamide during dissolution Eur. J. Pharm. Sci. 4 1996 S187 P3.087
5. G.V. Bertageri, and K.R. Makarla Characterization of glyburide polyethylene glycol solid dispersions Drug Dev. Ind. Pharm. 22 1996 731 734
6. M. Iwata, and H. Ueda Dissolution properties of glibenclamide in combinations with polyvinylpyrrolidone Drug Dev. Ind. Pharm. 22 1996 1161 1165
7. N.M. Sanghavi, H. Venkatesh, and V. Tandel Solubilization of glibenclamide with β-cyclodextrin and its derivatives Drug Dev. Ind. Pharm. 20 1994 1275 1283
8. M. Valleri, P. Mura, F. Maestrelli, M. Cirri, and R. Ballerini Development and evaluation of glyburide fast dissolving tablets using solid dispersion technique Drug Dev. Ind. Pharm. 30 2004 525 534
9. R.J. Babu, and K.J. Pandit Enhancement of dissolution rate and hypoglicemic activity of glibenclamide with β-cyclodextrin S.T.P. Pharma Sci. 5 1995 196 200
10. J. Savolainen, K. Jarvinen, H. Taipale, P. Jarho, T. Loftsson, and T. Jarvinen Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms Pharm. Res. 15 1998 1696 1701
11. L. Illum Chitosan and its use as a pharmaceutical excipient Pharm. Res. 15 1998 1326 1331
12. O. Felt, P. Buri, and R. Gurny Chitosan: a unique polysaccharide for drug delivery Drug Dev. Ind. Pharm. 24 1998 979 993
13. W. Paul, and C.P. Sharma Chitosan, a drug carrier for the 21th century S.T.P. Pharma Sci. 10 2000 5 22
14. S. Shiraishi, M. Arahira, T. Imai, and M. Otagiri Enhancement of dissolution rates of several drugs by low molecular chitosan and alginate Chem. Pharm. Bull. 38 1990 185 187
15. A. Portero, C. Remuñan-Lopez, and J.L. Vila-Jato Effect of chitosan and chitosan glutamate enhancing the dissolution properties of the poorly water soluble drug nifedipine Int. J. Pharm. 175 1998 75 84
16. P. Mura, N. Zerrouk, N. Mennini, F. Maestrelli, and C. Chemtob Development and characterization of naproxen-chitosan solid systems with improved drug dissolution properties Eur. J. Pharm. Sci. 19 2003 67 75
17. N. Zerrouk, N. Mennini, F. Maestrelli, C. Chemtob, and P. Mura Comparison of the effect of chitosan and polyvynilpyrrolidone on dissolution properties and analgesic effect of naproxen, Eur J. Pharm. Biopharm. 57 2004 93 99
18. K.H. Fromming, and J. Szejtli Cyclodextrins in Pharmacy 1994 Kluwer Academic Publishers Dordrecht
19. K. Uekama, F. Hirayama, and I. Tetsumi Cyclodextrin drug carrier systems Chem. Rev. 98 1998 2045 2076
20. M. Másson, T. Loftsson, G. Másson, and E. Stefánsson Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing J. Control. Rel. 59 1999 107 118
21. T. Irie, and K. Uekama Cyclodextrins in peptide and protein delivery Adv. Drug Del. Rev. 36 1999 101 123
22. H. Matsuda, and H. Arima Cyclodextrins in transdermal and rectal delivery Adv. Drug Del. Rev. 36 1999 81 99
23. E. Redenti, C. Pietra, A. Gerloczy, and L. Szente Cyclodextrins in oligonucleotide delivery Adv. Drug Del. Rev. 53 2001 235 244
24. Y. Kaji, K. Uekama, H. Yoshikawa, K. Takada, and S. Muranishi Selective transfer of 1-hexylcarbamoyl-5-fluorouracil into lymphatics by combination of β-cyclodextrin polymer complexation and absorption promotor in the rat Int. J. Pharm. 24 1985 79 89
25. K. Uekama, T. Kondo, and K. Nakamura Modification of rectal absorption of morphine from suppositories with a combination of α-cyclodextrin and viscosity-enhancing polymer J. Pharm. Sci. 84 1995 15 20
26. S.Y. Lin, and J.C. Yang Effect of β-cyclodextrin on the in-vitro permeation rate and in-vivo rectal absorption of acetaminophen hydrogel preparations Pharm Acta Helv. 65 1990 262 268
27. P. Artursson Cell culture as models for drug absorption across the intestinal mucosa Crit. Rev. Ther. Drug Carrier Syst. 8 1991 105 130
28. H. Lennernäs, K. Palm, U. Fagerholm, and P. Artusson Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo Int. J. Pharm. 127 1996 103 107
29. A.F. Kotzé, B.J. de Leeuw, H.L. Lueßen, A.G. de Boer, J.C. Verhoef, and H.E. Junginger Chitosans for enhanced delivery of therapeutics peptides across intestinal epithelia: in vitro evaluation in Caco-2 cell monolayers Int. J. Pharm. 159 1997 243 253
30. V. Pade, and S. Stavchansky Link between drug absorption solubility and permeability measurements in Caco-2 cells J. Pharm. Sci. 87 1998 1604 1607
31. G. Borchard, H.L. Lueßen, A.G. de Boer, J.C. Verhoef, C. Lehr, and H.E. Junginger The potential of mucoadhesive polymer in enhancing intestinal peptide drug absorption. III. Effect of chitosan-glutamate and carbomer on epithelial tight junctions in vitro J. Control. Rel. 39 1996 131 138
32. C. Korzeniewski, and D.M. Callewaert An enzyme-release assay for natural cytotoxicity J. Immunol. Methods 64 1983 313 320
33. G. Konjevic, V. Jurisic, and I. Spuzic Corrections to the original LDH release assay for the evaluation of NK cell cytotoxicity J. Immunol. Methods 200 1997 199 201
34. T. Higuchi, and K.A. Connors Phase-solubility techniques Adv. Anal. Chem. Instrum. 4 1965 117 212
35. P. Mura, G.P. Bettinetti, A. Manderioli, M.T. Faucci, G. Bramanti, and M. Sorrenti Interactions of ketoprofen and ibuprofen with ß-cyclodextrins in solution and in the solid state Int. J. Pharm. 166 1998 189 203
36. P. Mura, N. Zerrouk, M.T. Faucci, F. Maestrelli, and C. Chemtob Comparative study of ibuproxam complexation with amorphous ß-cyclodextrin derivatives in solution and in the solid state Eur. J. Pharm. Biopharm. 54 2002 181 191
37. P. Artursson, T. Lindmark, S.S. Davis, and L. Illum Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco2) Pharm. Res. 11 1994 1358 1361
38. N.G.M. Schipper, M.V. Kjell, and P. Artursson Chitosan as absorption enhancers for poorly absorbable drugs.1. Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells Pharm. Res. 13 1996 1686 1692
39. L. Hovgaard, and H. Brondsted Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins Pharm. Res. 12 1995 1328 1332
40. K. Yunomae, H. Arima, F. Hirayama, and K. Uekama Involvement of cholesterol in the inhibitory effect of dimethyl-β-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells FEBS Lett. 536 2003 225 231
41. B. Haeberlin, T. Gengenbacher, A. Meinzer, and G. Fricker Cyclodextrins - useful excipients for oral peptide administration? Int. J. Pharm. 137 1996 103 110
42. H. Arima, K. Yunomae, F. Hirayama, and K. Uekama Contribution of P-glycoprotein to the enhancing effects of dimethyl-β-cyclodextrin on oral bioavailability of tacrolimus J. Pharmacol. Exp. Therap. 297 2001 547 555
43. H. Vihola, A. Laukkanen, L. Valtola, H. Tenhu, and J. Hirvonen Cytotoxicity of thermosensitive polymers poly(N-isopropylacrylamide), poly(N-vinylcaprolactam) and amphiphilically modified poly(N-vinylcaprolactam) Biomaterials 26 2005 3055 3064
44. Z. Zuo, G. Twon, B. Stevenson, J. Diakur, and L.I. Wiebe Flutamide-hydroxypropyl-β-cyclodextrin complex: formulation, physical characterization and absorption studies using the Caco-2 in vitro model J. Pharm. Pharmaceut. Sci. 3 2000 220 227
45. J. Phillips, A. Arena. Optimization of Caco-2 cell growth and differentiation for drug transport studies, Millipore Corporation Protocol Note PC1060EN00, 2003.
46. T. Yang, A. Hussain, J. Paulson, T.J. Abbruscato, and F. Ahsan Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies Pharm Res. 21 2004 1127 1136
47. P.E. Golstein, A. Boom, J. Van Geffel, P. Jacobs, B. Masereel, and R. Beauwens P-glycoprotein inhibition by glibenclamide and related compounds Pflugers Arch. Eur. J. Physiol. 437 1999 652 660